Bristol Immune Drug Success in Cancer May Spur Industry Race

The early success of an experimental drug from Bristol-Myers Squibb Co. that’s designed to unleash the body’s immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.